Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interleukin-2 in cancer therapy.

D R Parkinson1

  • 1Department of Clinical Immunology and Biological Therapy, University of Texas, M.D. Anderson Cancer Center, Houston 77030.

Seminars in Oncology
|December 1, 1988
PubMed
Summary

Interleukin-2 (IL-2) modifies the immune system for antitumor effects. While effective in some refractory cancers, optimizing IL-2 therapy requires exploring doses, schedules, and combinations with other agents.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Educating for personalized medicine: a perspective from oncology.

Clinical pharmacology and therapeutics·2009
Same author

Anticancer drug discovery and development throughout the world.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2002
Same author

Immunodominance across HLA polymorphism: implications for cancer immunotherapy.

Journal of immunotherapy (Hagerstown, Md. : 1997)·1998
Same author

High-dose aldesleukin in renal cell carcinoma: long-term survival update.

The cancer journal from Scientific American·1998
Same author

Antisense oligonucleotides as therapeutics for malignant diseases.

Seminars in oncology·1997
Same author

Clinical implications of tumor-associated neovascularization and current antiangiogenic strategies for the treatment of malignancies of pancreas.

Cancer·1996

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Interleukin-2 (IL-2) is a biological response modifier with indirect antitumor effects.
  • Unlike alpha-interferon, IL-2's efficacy is dose and schedule dependent.
  • IL-2 shows antitumor activity alone and can be enhanced with other agents or lymphocytes.

Purpose of the Study:

  • To review the antitumor activity and toxicity of Interleukin-2 (IL-2).
  • To explore methods for increasing IL-2's antitumor activity and tolerability.
  • To discuss the role of IL-2 in treating refractory tumors.

Main Methods:

  • Review of existing data on IL-2 administration, efficacy, and toxicity.
  • Analysis of IL-2's pharmacokinetic profile and clearance mechanisms.
  • Comparison of continuous infusion versus bolus administration of IL-2.

Main Results:

  • IL-2 exhibits dose and schedule-related antitumor activity.
  • Continuous infusion of IL-2 is more toxic and biologically active than bolus administration.
  • A minority of patients achieve durable responses, particularly in refractory tumors.

Conclusions:

  • IL-2 therapy can induce responses in tumors resistant to conventional treatments.
  • Optimizing IL-2 therapy may involve alternative doses, schedules, and combinations.
  • Further research is needed to determine if IL-2 toxicity is essential for optimal clinical outcomes.

Related Experiment Videos